Breast Cancer Specific Markers and Methods of Use
The present invention relates to breast cancer biomarkers useful for the detection, diagnosis and therapeutic treatment of breast cancer.
1 . A plurality of polynucleotides, wherein the plurality consists of polynucleotides that bind specifically to nucleic acids encoding no more than 100 breast cancer markers, wherein the breast cancer markers comprise PTCD2, SLC25A20, NFKB2 and RASGRP2.
2 . A plurality of polynucleotides, wherein the plurality consists of polynucleotides that bind specifically to nucleic acids encoding no more than 100 breast cancer markers, wherein the breast cancer markers comprise PTCD2, PDE7A and MLL.
3 . A plurality of polynucleotides, wherein the plurality consists of polynucleotides that bind specifically to nucleic acids encoding no more than 100 breast cancer markers, wherein the breast cancer markers comprise PTCD2, PRKCE, GPATC3, PRIC285 and GSTA4.
4 . A plurality of isolated antibodies, wherein the plurality comprises antibodies that bind specifically to PTCD2, SLC25A20, NFKB2 and RASGRP2 polypeptides.
5 . A plurality of isolated antibodies, wherein the plurality comprises antibodies that bind specifically to PTCD2, PDE7A and MLL polypeptides.
6 . A plurality of isolated antibodies, wherein the plurality comprises antibodies that bind specifically to PTCD2, PRKCE, GPATC3, PRIC285 and GSTA4 polypeptides.
7 . A plurality of isolated breast cancer marker polypeptides, wherein the plurality comprises PTCD2, SLC25A20, NFKB2 and RASGRP2 polypeptides, or antigenic fragments thereof.
8 . A plurality of isolated breast cancer marker polypeptides, wherein the plurality comprises PTCD2, PDE7A and MLL polypeptides, or antigenic fragments thereof.
9 . A plurality of isolated breast cancer marker polypeptides, wherein the plurality comprises a PTCD2, PRKCE, GPATC3, PRIC285 and GSTA4 polypeptides, or antigenic fragments thereof.
10 . A plurality of polynucleotides, wherein the plurality consists of polynucleotides that bind specifically to nucleic acids encoding no more than 100 breast cancer markers, wherein the breast cancer markers comprise SLC25A20, NFKB2 and RASGRP2.
11 . The plurality of polynucleotides of claim 10 , wherein the breast cancer markers comprise MIPEP, PLCB2, SLC25A19, DEF6, ZNF236, C18orf22, COX7A2, DDX11, TOP3A, C9orf6, UFC1, PFDN2, KLRD1, LOC643641, HSP90AB1, CLCN7, TNFAIP2, PRKCE, MRPL40, FBF1, ANKRD44, CCT5, USP40, UBXD4, LRCH1, MRPL4, SCCPDH, STX6, LOC284184, FLJ23235, GPATC3, CPSF4, CREM, HIST1H1D, HPS4, FN3KRP, ANKRD16, C8 orf16, ATF71P2, and PRIC285.
12 . A plurality of isolated antibodies, wherein the plurality comprises antibodies that bind specifically to SLC25A20, NFKB2 and RASGRP2 polypeptides.
13 . A plurality of isolated breast cancer marker polypeptides, wherein the plurality comprises SLC25A20, NFKB2 and RASGRP2 polypeptides, or antigenic fragments thereof.
14 . A plurality of polynucleotides, wherein the plurality consists of polynucleotides that bind specifically to nucleic acids encoding no more than 100 breast cancer markers, wherein the breast cancer markers comprise PDE7A, MLL, and PTCD2.
15 . The plurality of polynucleotides of claim 14 , wherein the breast cancer markers comprise ZNF669, SNRP70, MGC35402, GSTA4, ATHL1, PRSS23, and TMEM80.
16 . The plurality of polynucleotides of claim 14 , wherein the breast cancer markers comprise FLJ40432 STX5A, PRKCE, MTMR11, TNPO1, MGC3731, FKBP5, C3orf62, IRS2, GPATC3, SUSD1, CCM2, ZBTB7A, RAB11A, GSDML, MAPK9, DRG2, PDZD8, LOC339804, PPARD, DDIT3, FAM113A, RHBDD3, TIMM44, ATP6AP2, ME2, PRIC285, TNFSF14, ABCA2, EML2, Magmas, EVI2A, USP37, GATAD1, CHN2, PSCD4, CHTF18, SFRS8, DICER1, and PIAS1.
17 . A plurality of isolated antibodies, wherein the plurality comprises antibodies that bind specifically to PDE7A, MLL, and PTCD2 polypeptides.
18 . A plurality of isolated breast cancer marker polypeptides, wherein the plurality comprises PDE7A, MLL, and PTCD2 polypeptides, or antigenic fragments thereof.
19 . The plurality of breast cancer marker polypeptides of claim 18 , wherein the plurality comprises ZNF669, SNRP70, MGC35402, GSTA4, ATHL1, PRSS23, and TMEM80, or antigenic fragments thereof.
20 . The plurality of breast cancer marker polypeptides of claim 19 , wherein the plurality comprises FLJ40432 STX5A, PRKCE, MTMR11, TNPO1, MGC3731, FKBP5, C3orf62, IRS2, GPATC3, SUSD1, CCM2, ZBTB7A, RAB11A, GSDML, MAPK9, DRG2, PDZD8, LOC339804, PPARD, DDIT3, FAM113A, RHBDD3, TIMM44, ATP6AP2, ME2, PRIC285, TNFSF14, ABCA2, EML2, Magmas, EVI2A, USP37, GATAD1, CHN2, PSCD4, CHTF18, SFRS8, DICER1, and PIAS1, or antigenic fragments thereof.
21 . A diagnostic panel consisting of one or more polynucleotides and optionally at least one non-polynucleotide component, wherein the polynucleotides bind specifically to a nucleic acid encoding a breast cancer marker selected from the group consisting of ACAA2, SLC25A20, SREBF1, and MRPL40, and to no more than 100 breast cancer markers.
22 . A diagnostic panel comprising at least one antibody, wherein the antibody binds specifically to a breast cancer marker selected from the group consisting of ACAA2, SLC25A20, SREBF1, and MRPL40, or a combination thereof.
23 . A diagnostic panel comprising at least one breast cancer marker polypeptide selected from the group consisting of ACAA2, SLC25A20, SREBF1, and MRPL40.
24 . A method for detecting the presence of breast cancer in a patient, the method comprising:
(a) obtaining a biological sample from the patient; and
(b) detecting the level of expression of breast cancer markers in the biological sample using the plurality of polynucleotides of claim 1 , wherein a modulated level of expression as compared to a predetermined cut-off value for each breast cancer marker indicates the presence of breast cancer in the patient.
25 . A method for detecting the presence of breast cancer in a patient, the method comprising:
(a) obtaining a biological sample from the patient; and
(b) detecting the level of protein expression of breast cancer markers in the biological sample using the plurality of antibodies of claim 4 , wherein a modulated level of protein expression as compared to a predetermined cut-off value for each breast cancer marker indicates the presence of breast cancer in the patient.
26 . A method for detecting the presence of breast cancer in a patient, the method comprising:
(a) obtaining a biological sample from the patient; and
(b) detecting the level of antibodies directed against breast cancer markers in the biological sample using the plurality of polypeptides of claim 7 , wherein a modulated level of antibodies as compared to a predetermined cut-off value for each breast cancer marker indicates the presence of breast cancer in the patient.